ArticlePerioperative medicine (London, England)2025
Soluble DLL1 as an Indicator of acute kidney injury and postoperative delirium following cardiac surgery: a secondary analysis of a prospective study.
Article in Perioperative medicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on biomarkers for acute kidney injury in children.Pediatric nephrology (Berlin, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) displays a common complication after cardiac surgery and must be diagnosed as early as possible. Soluble delta-like protein 1 (sDLL1) was originally evaluated as a sepsis biomarker but might also indicate other adverse outcomes. This study aims to investigate sDLL1 levels, examining its potential relationship with AKI and postoperative delirium (POD) after cardiac surgery and its predictive value.
methodsThis secondary analysis of a prospective observational trial included elective cardiac surgery patients. ELISA was used for the quantification of sDLL1. Statistical analysis involved repeated measures ANOVA and Pearson's correlation to assess associations between sDLL1 levels, renal, and inflammatory parameters. Receiver operating curves were used for prediction analysis.
resultsNinety patients were included in the study. Compared to patients without AKI, those with AKI (6.1%) showed significantly elevated plasma levels of sDLL1 postoperatively (no AKI 6308.49 [5121.27-7955.28], AKI 7,714.77 [7151.06-10,514.73] ng/mL; p = 0.01). Postoperative sDLL1 levels showed only a low predictive value for AKI (AUCROC 0.63, sensitivity 0.91, specificity 0.53). Postoperative sDLL1 measurements were also significantly elevated in patients with POD (23.3%). Further, postoperative sDLL1 plasma levels showed a moderate prediction for the identification of POD (AUCROC 0.72, sensitivity 0.64 specificity 0.73).
conclusionThis study demonstrates that sDLL1 provides moderate predictive value for AKI and POD after cardiac surgery and may provide valuable insights into postoperative complications. sDLL1 levels increase independently of CPB type, suggesting a role in the inflammatory response to the cardiopulmonary bypass and surgical stress rather than specific renal injury.
trial registrationDRKS00010959.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.